Back to Journals » Neuropsychiatric Disease and Treatment » Volume 16

Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease

Authors Saito Y, Sakata M, Kobayakawa M, Kawachi H, Kawaguchi K, Hiki Y, Kato M, Mori M, Hasegawa M, Ohashi N, Yuzawa Y, Kitaguchi N

Received 4 December 2019

Accepted for publication 14 February 2020

Published 3 March 2020 Volume 2020:16 Pages 607—627

DOI https://doi.org/10.2147/NDT.S241074

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Taro Kishi


Yuta Saito, 1–3 Miwa Sakata, 3 Moe Kobayakawa, 3 Hiroshi Kawachi, 4 Kazunori Kawaguchi, 3 Yoshiyuki Hiki, 3 Masao Kato, 1 Mayuko Mori, 1, 3 Midori Hasegawa, 1 Norimi Ohashi, 4 Yukio Yuzawa, 1 Nobuya Kitaguchi 3

1Department of Nephrology, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan; 2Graduate School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan; 3Faculty of Clinical Engineering, School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan; 4Ogaki Municipal Hospital, Ogaki, Gifu, Japan

Correspondence: Nobuya Kitaguchi 4-8-17, Yuzato, Higashisumiyosi-ku, Osaka 546-0013, Japan
Tel/Fax +81-6-3-4392-7087
Email nkitaguc@fujita-hu.ac.jp

Purpose: Amyloid-β protein (Aβ) is one of the causative proteins of Alzheimer’s disease. We have been developing extracorporeal blood Aβ-removal systems as a method for enhancing Aβ clearance from the brain. We reported previously that medical adsorbents and hemodialyzers removed Aβ monomers from peripheral blood, which was associated with influx of Aβ monomers from the brain into the bloodstream. Our intent here was to develop a method to promote clearance of Aβ oligomers and to provide an estimate of the molecular size of intact Aβ oligomers in plasma.
Methods: Two hollow-fiber devices with different pore sizes (Membranes A and B) were evaluated as removers of Aβ oligomers with human plasma in vitro. The concomitant removal of Aβ oligomers and monomers was investigated by using Membrane B and hexadecyl alkylated cellulose beads or polysulfone hemodialyzers. Double-filtration plasmapheresis with Membrane A was investigated as an approach for the removal of plasma Aβ oligomers in humans.
Results: Aβ oligomers were effectively removed by both Membranes A and B. The increase of Aβ oligomers in plasma was observed just after the removal of plasma Aβ oligomers in humans. The intact molecular size of major Aβ oligomers in the plasma was estimated to be larger than albumin at approximately 60 kDa or more. Additionally, the concomitant removal of Aβ monomers and oligomers evoked dissociation of larger Aβ oligomers into smaller ones and monomers.
Conclusion: Aβ oligomers were cleared from plasma both in vitro and in human subjects by using hollow-fiber membranes with large pores, indicating that their intact sizes were mostly larger than 60 kDa. Aβ oligomers in peripheral circulation were increased after some clearances in human. Further investigation will determine whether the Aβ oligomers detected in circulation after clearance were via influx from the brain.

Keywords: Aβ, amyloid beta, oligomer, Alzheimer’s disease, blood purification, membrane separation


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]